A New Treatment Option for Patients The U.S. Food and Drug Administration (FDA) has officially approved Pimjetmi (pimicotinib), a significant advancement for adult patients living with tenosynovial giant cell tumor (TGCT). This condition is a rare, non-malignant tumor that affects the synovium, bursae, and tendon sheaths, often causing severe pain, joint swelling, and significant functional…